GlaxoSmithKline (GSK) Receives “Neutral” Rating from JPMorgan Chase & Co.

JPMorgan Chase & Co. reaffirmed their neutral rating on shares of GlaxoSmithKline (NYSE:GSK) in a research note released on Thursday morning.

A number of other equities research analysts have also weighed in on GSK. Zacks Investment Research lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research note on Wednesday, January 10th. ValuEngine lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research note on Sunday, December 31st. Investec lowered shares of GlaxoSmithKline from a buy rating to a hold rating in a research note on Monday, November 6th. Bank of America lowered shares of GlaxoSmithKline from a buy rating to a neutral rating in a research note on Thursday, October 26th. Finally, Cowen set a $38.00 target price on shares of GlaxoSmithKline and gave the company a hold rating in a research note on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Hold and an average target price of $38.57.

Shares of GlaxoSmithKline (NYSE:GSK) traded up $0.66 during trading on Thursday, reaching $37.50. 4,989,600 shares of the company’s stock were exchanged, compared to its average volume of 5,400,000. The company has a market cap of $92,080.00, a price-to-earnings ratio of 28.85, a PEG ratio of 2.15 and a beta of 0.97. GlaxoSmithKline has a 1-year low of $34.52 and a 1-year high of $44.53. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64.

GlaxoSmithKline (NYSE:GSK) last announced its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%. sell-side analysts expect that GlaxoSmithKline will post 2.9 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Thursday, January 11th. Stockholders of record on Friday, November 10th were paid a dividend of $0.5037 per share. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. The ex-dividend date of this dividend was Thursday, November 9th. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.37%. GlaxoSmithKline’s payout ratio is presently 156.92%.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the stock in a transaction that occurred on Monday, November 6th. The stock was bought at an average cost of $14.00 per share, with a total value of $5,999,994.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 10.00% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wealthcare Advisory Partners LLC lifted its position in GlaxoSmithKline by 1,982.8% during the 3rd quarter. Wealthcare Advisory Partners LLC now owns 3,520 shares of the pharmaceutical company’s stock valued at $143,000 after acquiring an additional 3,351 shares during the period. FTB Advisors Inc. lifted its position in GlaxoSmithKline by 16.9% during the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company’s stock valued at $146,000 after acquiring an additional 539 shares during the period. Advisory Services Network LLC lifted its position in GlaxoSmithKline by 24.2% during the 2nd quarter. Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company’s stock valued at $175,000 after acquiring an additional 788 shares during the period. Quadrant Capital Group LLC lifted its position in GlaxoSmithKline by 3.5% during the 2nd quarter. Quadrant Capital Group LLC now owns 4,345 shares of the pharmaceutical company’s stock valued at $162,000 after acquiring an additional 148 shares during the period. Finally, Coastline Trust Co purchased a new position in GlaxoSmithKline during the 2nd quarter valued at about $202,000. 9.80% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “GlaxoSmithKline (GSK) Receives “Neutral” Rating from JPMorgan Chase & Co.” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://stocknewstimes.com/2018/01/15/glaxosmithkline-gsk-receives-neutral-rating-from-jpmorgan-chase-co.html.

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply